Insulin Glargine Injection 100IU/mL 3ml Cartridge | GMP Manufacturer & Supplier | Sinophare

Insulin Glargine Injection 100IU/mL 3ml Cartridge | Long-Acting Basal Insulin
  • Dosage: 100 IU/mL, 3ml cartridge
  • Volume: 3ml cartridge 
  • Packaging: Sterile cartridge for injection, 3ml cartridge/tray*1 box*10/catron
  • Shelf Life: 36 months 

Click to add this item to cart.

Product Description

Product NameInsulin Glargine Injection (Long-Acting Basal Insulin Analogue, Recombinant DNA Origin)
Specification100 IU/mL — 3mL Cartridge (300 IU total)
Dosage FormSterile, Nonpyrogenic, Clear, Colorless Aqueous Solution for Subcutaneous Injection (long-acting basal insulin analogue)
Active IngredientInsulin Glargine (recombinant DNA origin; human insulin analogue with A21 glycine substitution and two additional arginine residues at B30)
Pharmacological ClassAntidiabetic Agent / Pancreatic Hormone / Long-Acting Basal Insulin Analogue (Blood Glucose Regulating Agent)
Route of AdministrationSubcutaneous injection only (abdomen, thigh, deltoid, or buttock). NOT for intravenous or intramuscular injection. NOT to be mixed with any other insulin formulation.
Packaging3mL glass cartridge (for use with compatible insulin pen devices)
StorageUnopened: Store refrigerated at 2°C to 8°C, protected from light. Do NOT freeze. In-use (opened): Store at room temperature (below 25°C) for up to 28 days, away from direct heat and light. Discard after 28 days even if unused.
Shelf Life36 months (unopened, refrigerated)

Product Overview

Insulin Glargine Injection 100IU/mL 3mL Cartridge is a sterile, nonpyrogenic, clear, colorless aqueous solution of insulin glargine intended for subcutaneous injection. Each 3mL glass cartridge contains 300 IU (100 IU/mL) of insulin glargine. Insulin glargine is a long-acting basal insulin analogue produced by recombinant DNA technology, with specific amino acid modifications designed to provide a prolonged, peakless glucose-lowering profile. The product is formulated as a clear, acidic solution (pH approximately 4.0) in which insulin glargine remains fully soluble; upon subcutaneous injection into physiological pH tissue, the insulin glargine forms microprecipitates that slowly release insulin over an extended period, providing stable basal glycemic control.

<< return to products